Silexion Therapeutics Corp. has provided an update on its lead product, SIL204, a first-in-class, isoform-selective pan-KRAS silencer designed for targeted cancer therapy. The presentation highlights the use of siRNA technology to silence mutated KRAS, the most common oncogenic driver in several human cancers, including pancreatic, colorectal, and non-squamous non-small cell lung cancer. SIL204 is engineered for dual administration—systemic and intratumoral—to address both primary tumors and metastatic disease, particularly in pancreatic ductal adenocarcinoma (PDAC). The company reports that SIL204 binds extensively to low-density lipoproteins (LDLs), exploiting the increased LDL receptor expression in pancreatic cancer cells to enhance targeted delivery. Preclinical and Phase 2 clinical data from earlier siRNA candidates, as well as the development plan for SIL204, are included in the presentation. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silexion Therapeutics Corp. published the original content used to generate this news brief on February 03, 2026, and is solely responsible for the information contained therein.